Share this article
Share this article
LAUSANNE, Switzerland and BOSTON, Feb. 8, 2021 /PRNewswire/ SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy in resectable stage IIIA non-small cell lung cancer (NSCLC).
SOPHiA GENETICS and the Spanish Lung Cancer Group Team Up to Explore the Predictive Potential of Multimodal Health Data in Resectable Stage IIIA Non-Small Cell Lung Cancer
The collaboration with the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón GECP), a Spanish cooperative group for the research on lung cancer, is to show the potential of SOPHiA Radiomics a groundbreaking application that analyzes medical images for research use put to use in an additional retrospective analysis of the data from the phase 2 NADIM clinical trial (NCT03081